Table 4. Associations between baseline characteristics and response in patients treated at/above the RP2D, n=46.

Baseline characteristic	Response rate, n (%)
Age
<40 years	5/12 (41.7%)
<50 years	6/18 (33.3%)
<60 years	8/32 (25.0%)
≥60 years	7/14 (50.0%)
Secondary disease*
Yes	3/7 (42.9%)
No	12/39 (30.8%)
Duration of CR1
0 months (primary refractory)	4/18 (22.2%)
1-6 months	5/20 (25.0%)
7-12 months	3/4 (75.0%)
>12 months	3/4 (75.0%)
Salvage number
1	11/29 (37.9%)
2	3/12 (25.0%)
≥3	1/5 (20.0%)
Prior intermediate/high-dose cytarabine
Yes	10/35 (28.6%)
No	5/11 (45.5%)
Prior allogeneic HCT
Yes	5/13 (38.5%)
No	10/33 (30.3%)
Cytogenetic risk
Favorable/intermediate	12/26 (46.2%)
Adverse	3/20 (15.0%)

^*AML transformed from antecedent hematologic disorder or AML/MDS after prior cytotoxic therapy

Abbreviations: CR, complete remission; HCT, hematopoietic cell transplantation; RP2D, recommended phase 2 dose